Drug Database
CO

COVID-19 vaccine (Abdala / CIGB 66 / CIGB66)

✓ Approved

CIGB · 疫苗 · 疫苗

什么是 COVID-19 vaccine?

COVID-19 vaccine 是一种疫苗,由CIGB研发。该药已获批,用于治疗相关适应症,给药途径:Injectable (Others)、Intramuscular (IM) Injection。

药物档案

商品名Abdala, CIGB 66, CIGB66
公司CIGB
药物类别疫苗
给药途径Injectable (Others), Intramuscular (IM) Injection
状态Approved

治疗适应症

COVID-19 vaccine 针对 1 个适应症,涉及 1 个治疗领域。

治疗领域疾病/病症分期
Infections and infestationsCOVID-19✓ Approved

相关研究文献

PubMedInfection and immunity2026-11-17

Co-administration of DTaP with COVID-19 mRNA vaccine in mice alters immune responses and induces increased protection from Bordetella pertussis challenge.

Rader Nathaniel N, Boehm Dylan T DT, Bitzer Graham J GJ, Chapman Joshua J et al.

During the COVID-19 pandemic, children received COVID-19 mRNA vaccines alongside other regularly scheduled immunizations, such as the acellular Bordetella pertussis vaccine DTaP. It is known that mRNA vaccines are pro-inflammatory in nature, leading to protective immunity against SARS-CoV-2 infection. The goal of this study was to investigate the potential adjuvanticity of co-administration of a COVID-19 mRNA vaccine alongside DTaP. Mice were immunized with DTaP alone or with a co-administration of DTaP plus COVID-19 mRNA vaccine. To understand the impact of co-administration, we evaluated protection against B. pertussis aerosol challenge in mice and potential correlates of protection, including cytokine responses to vaccination, antibody responses, and single-cell transcriptomic analysis of the draining lymph node. Three decreasing doses of each vaccine were used to simulate waning immunity. Overall, compared to mice immunized with DTaP, co-administration of DTaP + COVID-19 mRNA vaccines elicited higher pro-inflammatory cytokine responses, higher IgG2b antibody responses, and mice were afforded increased protection against aerosol challenge of B. pertussis. Single-cell transcriptomics studies on the lymph node of vaccinated mice at 1 day post-boost further characterized how co-administration of COVID-19 mRNA vaccine alongside DTaP vaccine shapes immunity. Single-cell transcriptomics revealed that co-administration of DTaP and COVID-19 mRNA vaccine generated populations of B and T cells with upregulated expression of interferon-stimulated genes, which were absent when vaccinating with DTaP alone. Altogether, these data suggest that administering DTaP alongside COVID-19 mRNA vaccine alters immune responses and provides increased protection from an aerosol challenge of B. pertussis compared to DTaP alone in mice.

PMID 43043313
阅读全文 →
PubMedBMC public health2026-11-17

Post-introduction evaluation of COVID-19 vaccine deployment in Ghana: lessons learnt to inform future new vaccine introductions and strengthen public health readiness, 2023.

Amponsa-Achiano Kwame K, Shen Angela K AK, Baiden Laryea Eunice E, Carlton Julie Garon JG et al.

On March 2nd, 2021, Ghana, the first country to receive vaccines from the COVAX facility, began its COVID-19 vaccination using a complex multi-phased approach, to reach target populations. We evaluated the vaccine deployment to document best practices challenges and lessons for future new vaccine introductions and public health emergency readiness. We conducted a mixed methods post-introduction evaluation, purposively sampling 36 facilities from 12 districts in six regions. Adapting the World Health Organization's COVID-19 Post-Introduction Evaluation tool, we conducted a cross-sectional survey using a structured questionnaire, reviewed programme records, observed practices, and interviewed purposively selected health workers, immunization managers and partners who supported vaccine deployment. We performed summary descriptive statistics on quantitative data, thematic analysis on qualitative data, and triangulated the results. As of March 2023, more than 70% of the target population (15 years and older) had received at least one dose, while more than 50% had completed the primary series. Vaccine deployment was built on the existing immunisation programme and functional coordinating bodies. Cold chain capacity was revamped with ultra-low-temperature freezers, while 33.3% of surveyed districts adjusted waste disposal systems to accommodate COVID-19 vaccine introduction. Door-to-door delivery and demand generation through varied risk communication and community engagement strategies improved vaccine access. Electronic data platforms were established, surge capacity improved, and healthcare and community workers were trained. Initial unpredictable vaccine supplies limited vaccination efforts. Changing vaccine information affected health workers' ability to engage communities with up-to-date guidance. While vaccine safety monitoring systems were in place, reporting knowledge varied among health workers, and 36% of surveyed facilities had ever documented and reported COVID-19 vaccine-related adverse events following immunisation. Challenges with electronic data systems limited timely access to and use of granular service-delivery data for decision-making. Ghana leveraged existing immunisation and emergency-response systems to make substantial progress in COVID-19 vaccine deployment. Coordination, cold chain expansion, flexible service delivery, demand generation and workforce mobilisation supported implementation. Irregular vaccine supply, data system challenges, variable adverse event reporting, waste management pressure and misinformation challenged deployment. These findings provide lessons for adult immunisation, life-course vaccination and future public health emergency readiness.

PMID 43040294
阅读全文 →
PubMedGlobal epidemiology2026-11-17

Twelve-month all-cause mortality after initial COVID-19 vaccination with Pfizer-BioNTech or mRNA-1273 among adults living in Florida: Statewide cohort study.

Levi Retsef R, Mansuri Fahad F, Jordan Melissa M MM, Ladapo Joseph A JA

Comparative effects of the mRNA COVID-19 vaccines on health outcomes are uncertain. The study objective was to compare all-cause and non-COVID-19 mortality between recipients of BNT162b2 (Pfizer) and mRNA-1273 (Moderna). Matched cohort analysis of 1,962,822 adults living in Florida who received a first dose of either BNT162b2 or mRNA-1273 between December 18, 2020, and August 31, 2021, was used to examine 12-month risk of all-cause, cardiovascular, COVID-19, and non-COVID-19 mortality. Matching was performed on seven criteria, including age group, sex, race, ethnicity, calendar month of vaccination, nine types of vaccination sites, and 4832 census tracts. Kaplan-Meir estimators and Cox proportional hazards regressions were used. Compared with mRNA-1273 recipients, BNT162b2 recipients had higher hazard of all-cause mortality (784 vs. 562 deaths per 100,000; hazard ratio, HR [95% CI]: 1.40 [1.36, 1.45]), cardiovascular mortality (226 vs. 145 deaths per 100,000 persons; HR [95% CI]: 1.57 [1.47, 1.68]), COVID-19 mortality (61 vs. 32 deaths per 100,000 persons; HR [95% CI]: 1.91 [1.67, 2.19]) and non-COVID-19 mortality (722 vs. 530 deaths per 100,000 persons; HR [95% CI]: 1.37 [1.32, 1.42]). Negative control outcomes and robustness analyses did not show any indication of meaningful unobserved residual confounding likely to alter the results, although there was evidence of potential small residual imbalance among adults 60 years and older. Florida adults who received the BNT162b2 COVID-19 vaccine in the initial series had higher risk of 12-month all-cause, cardiovascular, COVID-19, and non-COVID-19 mortality compared to matched mRNA-1273 recipients, with differences in cardiovascular and COVID-19 mortality primarily driven by adults 60 and older. These findings suggest that COVID-19- and non-COVID-19-related health outcomes should be considered when evaluating vaccines targeting SARS-CoV-2. The study did not receive any external funding.

PMID 43041964
阅读全文 →
PubMedGeriatrie et psychologie neuropsychiatrie du vieillissement2026-11-17

[2026 vaccination schedule for adults aged 65 years and older: towards comprehensive vaccine-based prevention in older age].

Corroyer-Simovic Bénédicte B

The 2026 French vaccination schedule redefines geriatric prevention, extending its focus beyond the prevention of infectious diseases to the preservation of independence and functional health. Yet vaccination coverage in France remains inadequate. To address immunosenescence, the strategy prioritizes comprehensive protection against respiratory infections caused by influenza viruses, SARS-CoV-2, pneumococcus and respiratory syncytial virus (RSV). For influenza, guidelines recommend the preferential use of enhanced vaccines-either high-dose or adjuvanted formulations-to improve protection in older adults and reduce hospital admissions. Covid-19 boosters remain essential for this vulnerable population, with the adjuvanted recombinant protein vaccine Nuvaxovid® available alongside mRNA vaccines. Pneumococcal prevention is considerably simplified: a single dose of the 21-valent pneumococcal conjugate vaccine (PCV21, Capvaxive®) is recommended for all adults aged 65 years and older. This vaccine covers the serotypes responsible for 83.5% of invasive pneumococcal disease cases in France in 2024. RSV vaccination is indicated for adults aged 75 years and older and for those aged 65 years and older with cardiopulmonary comorbidities, providing protection against severe disease and reducing hospital admissions during winter. Beyond respiratory infections, vaccination against herpes zoster with the adjuvanted recombinant vaccine Shingrix® is recommended for all adults aged 65 years and older. Recent data associate this vaccination not only with the prevention of postherpetic neuralgia but also with a reduced risk of stroke. Tdap-IPV boosters remain essential in the context of recent pertussis epidemics and the persistent risk of tetanus in older adults. Vaccine coadministration is safe and should be offered to improve coverage and reduce the number of visits required. When vaccination records are unavailable, the priority is to proceed with vaccination rather than delay protection. This proactive, integrated approach aims to address inadequate vaccination coverage, reduce mortality and preserve independence in older adults.

PMID 43042679
阅读全文 →
PubMedScientific reports2026-11-17

Linking surfactant proteins and genetic variants to COVID-19 severity.

Aldrich Brycen B, Sicher Natalie N, Zhang Shaoyi S, Mazur Lauren L et al.

COVID-19 presents with variable clinical severity. Surfactant proteins (SPs) are critical to lung function and host defense, but their role as biomarkers for COVID-19 severity, and the impact of SP genetic variants, remains unclear. Therefore, we asked whether plasma SP levels and SP genetic variants are associated with COVID-19 severity in adults. We conducted a cohort study of 261 adults with PCR-confirmed COVID-19, classified as non-severe (n = 117) or severe (n = 144) based on WHO severity criteria. Plasma SP-A, SP-B, and SP-D levels were measured. Genetic variants in SFTPA1, SFTPA2, SFTPB, SFTPC, and SFTPD were analyzed. Quantile regression, receiver operating curve analysis, and logistic regression were used to assess associations. To compare model performance, the corrected Akaike Information Criterion (AICC) was used. Mediation analysis evaluated interactions among SP-A levels, genetic variant and disease severity. Severe COVID-19 was associated with higher plasma SP-A (9.8 vs. 8.4 ng/mL, p = 0.04) and SP-B (4119.2 vs. 3137.2 ng/mL, p = 0.01) levels, but not SP-D. SP-A and SP-B showed moderate predictive value for severity (AUC = 0.71). Inclusion of plasma SP-A (AICC = 219.7) or SP-B (AICC = 221.0) levels along with demographics improved performance over the demographics-only model (AICC = 300.2). Although significance was lost after Bonferroni correction, rs10351 in SFTPA1 was associated with lower risk of severe disease (OR = 0.40, p = 0.03); and lower SP-A level. Mediation analysis suggested the association was driven by disease severity. No associations were found for other SP gene variants. Elevated SP-A and SP-B levels are associated with severe COVID-19 and may serve as biomarkers. Predictive models combining either SP-A or SP-B levels with clinical information offer strong potential for risk stratification. The SFTPA1 variant rs10351 may confer protection through reduced alveolar injury, though further validation is warranted. Clinical trial registration: ClinicalTrials.gov. Study ID# NCT04650191, 30th November, 2020.

PMID 43042647
阅读全文 →
PubMedJournal of racial and ethnic health disparities2026-11-17

Impact of Metabolic Syndrome on COVID-19 Outcomes and Gastrointestinal Health in an Urban African American Hospitalized Cohort.

Brim Hassan H, Imran Muhammad Ahmad MA, Vummaneni Siri S, Laiyemo Adeyinka O AO et al.

African American patients have experienced disproportionate morbidity and mortality from COVID-19, and metabolic syndrome (MetS) has emerged as a key contributor to adverse outcomes in this population. Adverse COVID-19 outcomes in African American patients may reflect a syndemic interaction of metabolic, inflammatory, and gastrointestinal (GI) processes rather than isolated risk factors. This study aimed to evaluate how metabolic syndrome, gastrointestinal manifestations, and metabolic-organ injury markers collectively relate to COVID-19 severity and outcomes among hospitalized African American patients. We conducted a retrospective cohort study of 1,221 African American patients hospitalized with COVID-19 at Howard University Hospital. Patients were categorized as having MetS (n = 318, 26%) or not having MetS (n = 903, 74%) based on American Heart Association criteria. Demographics, comorbidities, clinical presentation, laboratory findings, treatments, and outcomes were compared between groups, with age-adjusted analyses performed given baseline age differences. Patients with Metabolic syndrome were older (65.1 vs. 56.6 years) and had longer hospital stays (11.6 vs. 9.4 days) than patients without MetS. They also had higher ICU transfer rates (n = 77, 25.5% vs. n = 132, 15.5%; p = 0.001), greater prevalence of cardiometabolic comorbidities including cardiovascular disease (46.9% vs. 23.9%, p = 0.001) and chronic kidney disease (26% vs. 15.5%, p = 0.001), and more frequent GI symptoms (n = 127, 43.5% vs. n = 293, 35.4%; p = 0.01). Patients with MetS also required more intensive treatment, including higher rates of insulin use (66.3% vs. 21.8%) and glucocorticoids (45.1% vs. 36.5%), and showed greater laboratory evidence of organ dysfunction. In-hospital mortality was numerically higher among patients with MetS (n = 54, 17.5% vs. n = 110, 12.7%) but did not reach statistical significance (p = 0.42). Metabolic syndrome is associated with greater COVID-19 disease severity, critical care burden, and gastrointestinal involvement in African American patients, consistent with a syndemic interaction of metabolic, inflammatory, and gastrointestinal pathways. Targeted metabolic and gastrointestinal-focused interventions may help mitigate COVID-19 disparities in this population.

PMID 43040149
阅读全文 →

注册免费账户还可查看另外 9996 篇文献

免费注册查看全部文献 →

了解更多COVID-19 vaccine